Showing results (81-90 of 164) with videos related to
Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemiaEmmanuel Raffoux, Philippe Rousselot, Jöel Poupon, et al.Cytometry. Part B, Clinical Cytometry|November 27, 2024
Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemiaKim Pacchiardi, Victoire de Marcellus, Tony Huynh, et al.Haematologica|December 10, 2020
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical useAuriane Lesieur, Xavier Thomas, Olivier Nibourel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 studyCecile Pautas, Fatiha Merabet, Xavier Thomas, et al.Oncotarget|April 16, 2016
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemiaNorbert Vey, Jacques Delaunay, Giovanni Martinelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experienceCharikleia Kelaidi, Sylvie Chevret, Stéphane De Botton, et al.Haematologica|September 24, 2009
Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemiaSébastien Maury, Françoise Huguet, Thibaut Leguay, et al.Blood|July 10, 2014
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyHartmut Döhner, Michael Lübbert, Walter Fiedler, et al.Blood|September 6, 2019
Germline DDX41 mutations define a significant entity within adult MDS/AML patientsMarie Sébert, Marie Passet, Anna Raimbault, et al.Blood Advances|October 9, 2021
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AMLJuliette Lambert, Jerome Lambert, Xavier Thomas, et al.Pageof 17